Last reviewed · How we verify

ALIZAPRIDE

FDA-approved active Small molecule Under review Quality 10/100

ALIZAPRIDE is a alizapride drug. It is currently FDA-approved for Nausea and vomiting, Postoperative nausea and vomiting.

Alizapride is a small molecule dopamine D2 receptor antagonist. It has been studied in clinical trials for conditions such as chemotherapy-induced nausea and vomiting, nausea, and vomiting, including in patients with early breast cancer.

At a glance

Generic nameALIZAPRIDE
Drug classalizapride
TargetD(2) dopamine receptor
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ALIZAPRIDE

What is ALIZAPRIDE?

ALIZAPRIDE is a alizapride drug, indicated for Nausea and vomiting, Postoperative nausea and vomiting.

What is ALIZAPRIDE used for?

ALIZAPRIDE is indicated for Nausea and vomiting, Postoperative nausea and vomiting.

What drug class is ALIZAPRIDE in?

ALIZAPRIDE belongs to the alizapride class. See all alizapride drugs at /class/alizapride.

What development phase is ALIZAPRIDE in?

ALIZAPRIDE is FDA-approved (marketed).

What does ALIZAPRIDE target?

ALIZAPRIDE targets D(2) dopamine receptor and is a alizapride.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing